1. Home
  2. COO vs XOMAP Comparison

COO vs XOMAP Comparison

Compare COO & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COO
  • XOMAP
  • Stock Information
  • Founded
  • COO 1980
  • XOMAP N/A
  • Country
  • COO United States
  • XOMAP United States
  • Employees
  • COO N/A
  • XOMAP 13
  • Industry
  • COO Ophthalmic Goods
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • Sector
  • COO Health Care
  • XOMAP Health Care
  • Exchange
  • COO Nasdaq
  • XOMAP Nasdaq
  • Market Cap
  • COO N/A
  • XOMAP N/A
  • IPO Year
  • COO N/A
  • XOMAP N/A
  • Fundamental
  • Price
  • COO $94.50
  • XOMAP $25.87
  • Analyst Decision
  • COO Buy
  • XOMAP
  • Analyst Count
  • COO 12
  • XOMAP 0
  • Target Price
  • COO $117.00
  • XOMAP N/A
  • AVG Volume (30 Days)
  • COO 1.6M
  • XOMAP N/A
  • Earning Date
  • COO 12-05-2024
  • XOMAP N/A
  • Dividend Yield
  • COO N/A
  • XOMAP N/A
  • EPS Growth
  • COO 32.43
  • XOMAP N/A
  • EPS
  • COO 1.96
  • XOMAP N/A
  • Revenue
  • COO $3,895,400,000.00
  • XOMAP N/A
  • Revenue This Year
  • COO $8.92
  • XOMAP N/A
  • Revenue Next Year
  • COO $6.74
  • XOMAP N/A
  • P/E Ratio
  • COO $48.40
  • XOMAP N/A
  • Revenue Growth
  • COO 8.41
  • XOMAP N/A
  • 52 Week Low
  • COO $84.76
  • XOMAP N/A
  • 52 Week High
  • COO $112.38
  • XOMAP N/A
  • Technical
  • Relative Strength Index (RSI)
  • COO 28.83
  • XOMAP 51.26
  • Support Level
  • COO $93.42
  • XOMAP $25.52
  • Resistance Level
  • COO $100.47
  • XOMAP $25.92
  • Average True Range (ATR)
  • COO 2.30
  • XOMAP 0.15
  • MACD
  • COO -0.73
  • XOMAP 0.00
  • Stochastic Oscillator
  • COO 3.86
  • XOMAP 87.23

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: